UltraGreen.ai invests $12.3m in LifeSignals, IHLD

The investments were funded from IPO proceeds and are not expected to materially affect FY2026 EPS.

UltraGreen.ai has used $12.3m (US$7.5m) of its initial public offering proceeds for convertible loans to LifeSignals Group and IHLD Med Tech as part of its strategic growth initiatives.

The company invested $5.8m (US$4.5m) in LifeSignals to support biosensor manufacturing, software enhancements, and working capital requirements.

LifeSignals’ biosensors are distributed internationally through UltraGreen.ai’s subsidiary, UltraGreen Data Systems.

The collaboration will support commercialisation under a new brand, UltraGreen Cardiac Technologies, which will represent the group’s cardiology distribution business.

UltraGreen.ai said the partnership is expected to contribute revenue through the sale and distribution of LifeSignals Holter devices, with an initial focus on the US and Europe.

LifeSignals is an associate of Renew Group, a controlling shareholder of UltraGreen.ai. The investment is therefore an interested person transaction, but does not require shareholders’ approval as it does not reach the relevant threshold under Chapter 9 of the Listing Manual.

UltraGreen.ai also invested $3.8m (US$3m) in IHLD Med Tech through a convertible loan to expand its fluorescence-guided platform into India’s wound care market. The investment may increase to up to $15.4m (US$12m), subject to agreed milestones.

The IHLD initiative will initially focus on wound care across cardiac, diabetic, trauma, and other clinical applications. Go-to-market activities are expected to begin in the next two to three months.

UltraGreen.ai said the LifeSignals and IHLD transactions are not expected to have any material impact on the group’s earnings per share for the financial year ending 31 December 2026.

Including $1.9m (US$1.5m) used for working capital and general corporate purposes, UltraGreen.ai has used $11.5m (US$9.0m) of its IPO proceeds, leaving a balance of $171.8m (US$134.1m). The company said the utilisation is in line with the intended use set out in its prospectus.

($1 = US$0.78)

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia